There is a pressing need to capture and track subtle cognitive change at the preclinical
stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

Alzheimer's disease (AD) is the most common form of dementia characterized
neuropathologically by senile plaques and neurofibrillary tangles (NFTs). Early …

Recent developments of PET amyloid ligands have made it possible to visualize the
presence of Aβ deposition in the brain of living participants and to assess the consequences …

Significant progress has been made in characterizing the biological changes occurring in
preclinical Alzheimer's disease (AD). Cognitive dysfunction has been viewed, however, as a …

Neurovascular dysfunction, including blood–brain barrier (BBB) breakdown and cerebral
blood flow (CBF) dysregulation and reduction, are increasingly recognized to contribute to …

Importance It is critically important to improve our ability to diagnose and track Alzheimer
disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can …

Importance Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD).
Understanding the association between amyloid aggregation and cognitive manifestation in …

Introduction This meta-analysis aimed to characterize the nature and magnitude of amyloid
(Aβ)-related cognitive impairment and decline in cognitively normal (CN) older individuals …